Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Avidity Biosciences Inc (RNA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/20/2025: RNA (3-star) is a REGULAR-BUY. BUY since 13 days. Profits (-14.82%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
15 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Year Target Price $69.2
Year Target Price $69.2
| 9 | Strong Buy |
| 6 | Buy |
| 0 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit 188.92% | Avg. Invested days 35 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 06/20/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 3.50B USD | Price to earnings Ratio - | 1Y Target Price 67.24 |
Price to earnings Ratio - | 1Y Target Price 67.24 | ||
Volume (30-day avg) - | Beta 0.95 | 52 Weeks Range 21.51 - 56.00 | Updated Date 06/29/2025 |
52 Weeks Range 21.51 - 56.00 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -8360.9% |
Management Effectiveness
Return on Assets (TTM) -22.47% | Return on Equity (TTM) -34.19% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2124791671 | Price to Sales(TTM) 391.92 |
Enterprise Value 2124791671 | Price to Sales(TTM) 391.92 | ||
Enterprise Value to Revenue 238.02 | Enterprise Value to EBITDA -5.72 | Shares Outstanding 120520000 | Shares Floating 91747772 |
Shares Outstanding 120520000 | Shares Floating 91747772 | ||
Percent Insiders 5.17 | Percent Institutions 112.42 |
Analyst Ratings
Rating 4.6 | Target Price 69.2 | Buy 6 | Strong Buy 9 |
Buy 6 | Strong Buy 9 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Avidity Biosciences Inc
Company Overview
History and Background
Avidity Biosciences Inc. was founded in 2012. It's a biopharmaceutical company focused on developing Antibody Oligonucleotide Conjugates (AOCs) as a new class of precision medicines. The company has focused on rare muscle diseases but is expanding into other areas.
Core Business Areas
- AOC Platform Technology: Avidity's core platform is based on Antibody Oligonucleotide Conjugates (AOCs) which combine the specificity of antibodies with the precision of oligonucleotide therapies to target the cause of diseases.
- Drug Development: Avidity is developing a pipeline of AOC therapies for various muscle diseases and other conditions. They conduct research, preclinical studies, and clinical trials to bring these therapies to market.
Leadership and Structure
The leadership team includes Sarah Boyce (President and CEO). The organizational structure involves research and development, clinical operations, manufacturing, and commercial functions.
Top Products and Market Share
Key Offerings
- AOC 1001 (Delpacibart etedesiran): AOC 1001 is Avidity's lead clinical program being developed for the treatment of myotonic dystrophy type 1 (DM1). Market share is currently negligible as the product is still in development. Competitors include Ionis Pharmaceuticals (IONIS) with Olezarsen, and Biogen (BIIB).
- AOC 1044: AOC 1044 is a program in preclinical development for Duchenne Muscular Dystrophy (DMD). Market share is currently negligible as the product is still in preclinical. Competitors include Sarepta Therapeutics (SRPT) and Solid Biosciences (SLDB).
Market Dynamics
Industry Overview
The biopharmaceutical industry is competitive and rapidly evolving, with significant investment in research and development. The market for targeted therapies is growing, driven by advances in genomics and personalized medicine.
Positioning
Avidity is positioned as a leader in AOC technology, a novel approach for treating diseases. Its competitive advantage lies in its proprietary AOC platform and its focus on difficult-to-treat diseases.
Total Addressable Market (TAM)
The total addressable market for Avidity's therapies is substantial, given the unmet needs in rare muscle diseases and other potential indications. Market size estimates for DM1 alone are in the billions of dollars annually. Avidity is positioned to capture a significant portion of this market with successful development and commercialization of its AOC therapies.
Upturn SWOT Analysis
Strengths
- Proprietary AOC technology platform
- Strong intellectual property portfolio
- Experienced management team
- Targeting diseases with high unmet medical needs
- Promising preclinical and clinical data
Weaknesses
- Early-stage company with no approved products
- Dependence on the success of its AOC platform
- High cash burn rate
- Reliance on collaborations for some aspects of development
- Potential for clinical trial failures
Opportunities
- Expansion of AOC platform to new disease areas
- Potential for strategic partnerships and collaborations
- Positive clinical trial results could drive significant value
- Increasing demand for targeted therapies
- Orphan drug designation and other regulatory incentives
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Intellectual property challenges
- Economic downturn impacting funding
Competitors and Market Share
Key Competitors
- IONIS
- SRPT
- BIIB
Competitive Landscape
Avidity's AOC platform offers a unique approach compared to traditional oligonucleotide therapies and gene therapies. It faces competition from companies with established products in the muscle disease space, but its AOC technology could provide a competitive advantage.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily reflected in the expansion of its pipeline and advancements in its AOC platform.
Future Projections: Future projections are highly dependent on the success of clinical trials, particularly AOC 1001. Analyst estimates vary widely. Expect growth in R&D, and potentially in revenue if clinical trials are successful.
Recent Initiatives: Recent initiatives include advancing AOC 1001 through clinical trials, expanding the AOC platform to new disease areas, and exploring strategic collaborations.
Summary
Avidity Biosciences is a promising early-stage biotech company with a novel AOC platform. Its strength lies in this innovative technology and its focus on diseases with unmet needs. However, it is a high-risk investment due to its early stage of development and reliance on clinical trial success. Potential investors should closely monitor clinical trial results and regulatory developments.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Avidity Biosciences Inc. website
- Company SEC filings
- Analyst reports
- Industry publications
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. The analysis is based on publicly available information and may be subject to change. Investments in biotech companies are highly speculative and involve significant risks.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Avidity Biosciences Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2013-06-28 | President, CEO & Director Ms. Sarah Boyce | ||
Sector Healthcare | Industry Biotechnology | Full time employees 391 | |
Full time employees 391 | |||
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics called antibody oligonucleotide conjugates (AOCs). Its AOC platform is designed to combine the specificity of monoclonal antibodies with the precision of RNA therapeutics to target the root cause of diseases previously untreatable with such therapeutics. The company's pipeline has three programs in registrational clinical trials, such as Delpacibart etedesiran, which is in Phase 3 development stage for the treatment of people with myotonic dystrophy type 1; Delpacibart braxlosiran that is in Phase 1/2 development stage for treating facioscapulohumeral muscular dystrophy; and Delpacibart zotadirsen, which is in the Phase 2 EXPLORE44 open-label extension study for the treatment of Duchenne muscular dystrophy. The company is also developing precision cardiology candidates targeting rare genetic cardiomyopathies, including AOC 1086 for phospholamban cardiomyopathy and AOC 1072 for protein kinase AMP-activated non-catalytic subunit gamma 2 syndrome. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.